1. Introduction

Biological Sovereignty Governance refers to the legal principles, constitutional safeguards, regulatory institutions, and international rules governing who has authority over biological resources, genetic materials, human biological data, and the use of biotechnology.

The concept addresses a fundamental question:

Who has the legal authority to control, access, protect, use, modify, commercialise, or benefit from biological resources and biological information?

This question has become increasingly important because advances in biotechnology allow biological materials to be collected, sequenced, stored, modified, transferred across borders, and used to develop commercial products.

Biological sovereignty governance can involve several different legal interests:

1. State sovereignty over biological resources: A country's authority to regulate access to genetic resources found within its jurisdiction.
2. Individual bodily autonomy: A person's rights concerning their body, tissues, reproductive materials, and genetic information.
3. Indigenous and community rights: The rights of Indigenous peoples and local communities concerning traditional knowledge and associated biological resources.
4. Genetic-data sovereignty: Legal control over the collection, storage, transfer, and secondary use of genomic information.
5. Scientific and research governance: The regulation of biological samples used in scientific research, clinical trials, and biotechnology development.
6. Commercial and intellectual-property governance: The legal allocation of rights and benefits arising from inventions developed using biological resources.
7. Environmental and biosecurity governance: The regulation of genetically modified organisms, invasive species, pathogens, and potentially dangerous biological materials.

These interests overlap, but they are not legally identical. A country may have sovereign rights to regulate access to a genetic resource without owning every biological sample collected within its territory. Similarly, a person may have privacy rights concerning their genetic information without automatically owning every invention developed through research involving that information.

An important qualification: Biological sovereignty governance is not a single, universally codified legal doctrine. It is an analytical framework derived from constitutional law, environmental law, human rights, biodiversity law, intellectual-property law, data protection, and biosecurity regulation.

The following discussion focuses primarily on Indian law, supplemented by important international and comparative judicial decisions.

2. Meaning and Scope of Biological Sovereignty

Biological sovereignty can be understood through four interconnected dimensions.

A. National biological sovereignty

National biological sovereignty concerns a State's authority to regulate biological resources within its jurisdiction.

Examples include:

• Medicinal plants and microorganisms.
• Agricultural and forest genetic resources.
• Wild species and their genetic material.
• Marine biological resources within national jurisdiction.
• Genetic resources used in pharmaceutical research.
• Biological materials used to develop industrial enzymes or agricultural technologies.

The principal international framework is the Convention on Biological Diversity (CBD).

Article 3 of the Convention recognises States' sovereign rights over their natural resources and their responsibility to ensure that activities within their jurisdiction or control do not damage the environment of other States or areas beyond national jurisdiction.

Article 15 recognises the sovereign rights of States over their natural resources and provides that authority to determine access to genetic resources rests with national governments, subject to national legislation.

The Convention therefore establishes an important distinction between the international principle of State sovereignty and the domestic legal rules governing ownership, access, use, and benefit-sharing. Convention on Biological Diversity

B. Individual biological sovereignty

Individual biological sovereignty is a broader analytical expression for a person's authority over their body and biological identity.

It includes legal interests relating to:

• Bodily integrity and informed consent.
• Medical treatment and experimentation.
• Collection and retention of biological samples.
• DNA profiling and genetic testing.
• Reproductive autonomy.
• Confidentiality of genetic information.
• Discrimination based on genetic characteristics.

In India, the constitutional foundation for many of these interests is found in Article 21 of the Constitution, which protects life and personal liberty, read alongside the fundamental rights to equality, freedom, and protection against certain forms of exploitation.

The Supreme Court's decision in Justice K.S. Puttaswamy (Retd.) v. Union of India (2017) established privacy as a fundamental right under the Constitution.

However, individual biological sovereignty does not necessarily mean absolute ownership over every biological substance or an unconditional right to prevent all lawful medical examinations, forensic investigations, or public-health interventions.

The legality of an intrusion depends on the applicable law, its purpose, procedural safeguards, and proportionality.

C. Community and Indigenous biological sovereignty

Indigenous peoples and local communities may possess traditional knowledge concerning medicinal plants, seeds, agricultural practices, and other biological resources.

Their legal interests can include:

• Recognition of customary knowledge.
• Participation in decisions affecting community resources.
• Prior informed consent where the applicable legal framework requires it.
• Fair and equitable sharing of benefits.
• Protection against unauthorised commercial exploitation.
• Preservation of culturally significant biological resources.

These interests are particularly important where companies or research institutions use community-associated knowledge to develop medicines, agricultural products, or other commercial innovations.

Community rights must nevertheless be distinguished from State sovereignty: a national government may regulate access to biological resources, while the community may possess separate rights under domestic law or applicable international instruments.

D. Digital biological sovereignty

Digital biological sovereignty concerns the governance of genomic sequences, DNA databases, biological datasets, and information generated through biotechnology.

For example, a research institution might sequence a plant collected in India and transfer the resulting genomic information to a foreign research database.

This raises several separate questions:

1. Was access to the original biological resource lawful?
2. Did the research comply with applicable access-and-benefit-sharing requirements?
3. Are there restrictions on transferring the resulting data?
4. Does the data contain personal or identifiable genetic information?
5. Does the relevant agreement require benefit-sharing or acknowledgment?
6. Are the resulting inventions subject to patent or other intellectual-property rules?

The answers depend on the resource, the parties, the relevant legislation, the date of collection, and the intended use.

A digital sequence is not automatically governed in exactly the same way as the physical biological material from which it was derived. The applicable legal framework must be examined carefully.

3. Legal Framework Governing Biological Sovereignty in India

India's legal framework distributes authority over biological resources among constitutional institutions, environmental regulators, biodiversity authorities, courts, and other statutory bodies.

A. Constitution of India

The Constitution does not expressly establish a single fundamental right called "biological sovereignty." Instead, relevant protections arise from several constitutional provisions.

These provisions operate together rather than creating an unlimited State power over biology.

For example, the government may regulate the collection of medicinal plants to conserve biodiversity. However, if an authority arbitrarily refuses a licence or imposes an unsupported restriction, its action may be challenged under applicable constitutional and statutory principles.

Similarly, a public authority's collection of genetic information may require scrutiny under Article 21 if it interferes with privacy or bodily autonomy.

B. Biological Diversity Act, 2002

The principal Indian legislation for regulating access to biological resources and associated traditional knowledge is the Biological Diversity Act, 2002, as amended.

The Act establishes a framework for three central objectives:

1. Conservation of biological diversity.
2. Sustainable use of its components.
3. Fair and equitable sharing of benefits arising from the use of biological resources and associated knowledge.

Its institutional structure includes the National Biodiversity Authority, State Biodiversity Boards, and Biodiversity Management Committees, with functions allocated by the legislation.

The Act is particularly important when biological resources are used commercially or for research and development.

Key provisions include:

• Section 3: Regulates specified access by certain persons, including relevant foreign individuals and entities.
• Section 4: Addresses the transfer of research results relating to Indian biological resources to specified foreign persons or entities, subject to the statutory framework.
• Section 6: Regulates specified applications for intellectual-property rights based on research or information on biological resources obtained from India.
• Section 7: Addresses access by Indian persons or entities within its scope, subject to statutory exceptions and the applicable amended framework.
• Sections 18–21: Address the National Biodiversity Authority's functions, approvals, and benefit-sharing arrangements.
• Sections 22–24: Establish or define relevant State Biodiversity Board functions and powers.
• Section 41: Provides for Biodiversity Management Committees at the local level.

The precise obligations depend on the applicable statutory version, the identity and status of the applicant, the nature of the resource, the purpose of access, and any applicable exemptions.

Official legislation and statutory materials can be consulted through India Code.

Important distinction: The Act does not mean that every biological resource belongs to the central government in the ordinary private-property sense. It establishes regulatory authority, conservation obligations, and access-and-benefit-sharing arrangements. Questions of ownership, possession, land rights, community rights, and permissible use must be considered separately.

C. Biological Diversity Amendment Act, 2023

The Biological Diversity Amendment Act, 2023 introduced changes to the original statutory framework, including changes relevant to access, research, traditional knowledge, and compliance.

Consequently, legal analysis must identify which version of the Act applies to the relevant conduct.

A dispute involving an older collection of biological material may raise different issues from a new commercial access arrangement. Transitional provisions, exemptions, amended definitions, and the timing of the conduct may affect the result.

A researcher or company should therefore avoid assuming that a rule described in an older judgment necessarily applies unchanged to every transaction governed by the amended legislation.

D. International legal instruments

Several international instruments contribute to biological sovereignty governance.

1. Convention on Biological Diversity, 1992

The Convention recognises State sovereignty over natural resources while promoting conservation, sustainable use, and fair benefit-sharing.

2. Nagoya Protocol, 2010

The Nagoya Protocol develops the access-and-benefit-sharing framework for genetic resources and associated traditional knowledge.

Article 5 addresses fair and equitable benefit-sharing. Article 6 addresses access to genetic resources, including prior informed consent where required by the applicable framework. Article 7 addresses access to traditional knowledge associated with genetic resources.

The Protocol also addresses mutually agreed terms, which may specify benefit-sharing, subsequent third-party use, and related conditions. Convention on Biological Diversity

3. Cartagena Protocol on Biosafety, 2000

This instrument concerns the safe handling, transport, and use of living modified organisms resulting from modern biotechnology, particularly where they may adversely affect biodiversity, taking account of risks to human health.

4. International Treaty on Plant Genetic Resources for Food and Agriculture

This treaty establishes a multilateral system for access to specified plant genetic resources for food and agriculture and for sharing benefits arising from their use.

These instruments address different legal questions. They should not be treated as establishing one universal ownership regime for all biological materials.

4. Leading Indian Case Laws on Biological Sovereignty Governance

The following decisions provide important legal foundations for the subject. Some directly concern biological resources; others concern the constitutional principles that govern biological data, bodily integrity, and the exercise of State authority.

Case 1: Divya Pharmacy v. Union of India and Others

Court: Uttarakhand High Court
Decision: 21 December 2018
Case: Writ Petition (M/S) No. 3437 of 2016

Facts

Divya Pharmacy manufactured Ayurvedic and nutraceutical products using biological resources as ingredients.

The company challenged demands for fair and equitable benefit-sharing made under the Biological Diversity Act, 2002, arguing, among other things, that the relevant obligations did not extend to an Indian entity without foreign participation in the circumstances of the case.

The dispute raised a significant question: could benefit-sharing obligations apply to an Indian commercial enterprise using biological resources, even where the enterprise did not have the foreign element on which the petitioner relied?

Legal issue

Whether the State Biodiversity Board could demand fair and equitable benefit-sharing from the petitioner under the applicable statutory provisions and regulations.

Judgment

The Uttarakhand High Court rejected the challenge and upheld the authority to impose the relevant benefit-sharing obligations under the statutory framework considered in the judgment.

The Court examined the relationship between the Act's provisions, the powers of the State Biodiversity Board, and the objectives of biodiversity conservation and benefit-sharing.

The judgment treated the statutory framework as supporting the equitable sharing of benefits arising from commercial use of biological resources, including in the circumstances before it. Indian Kanoon

Legal principles

The decision is important for three reasons.

First, commercial use can create benefit-sharing obligations. A business cannot necessarily avoid statutory biodiversity obligations simply by asserting that it is domestically incorporated.

Second, biological resources have a community and conservation dimension. Their commercial exploitation may raise issues beyond the immediate relationship between the business and the person who supplied the material.

Third, regulatory authority must derive from legislation. Benefit-sharing obligations must be connected to the statutory framework and exercised by the legally competent authority.

Significance for biological sovereignty

This case is particularly relevant to the economic dimension of biological sovereignty.

It illustrates how a State may regulate the commercial use of biological resources while seeking to ensure that benefits are shared in accordance with the law.

However, the decision should not be interpreted as establishing that every biological resource is automatically State-owned or that every use necessarily attracts the same benefit-sharing obligation.

The applicability of the amended Act and its exemptions must be assessed separately for later transactions.

Case 2: Justice K.S. Puttaswamy (Retd.) v. Union of India

Court: Supreme Court of India
Decision: 24 August 2017
Citation: (2017) 10 SCC 1

Facts and legal background

The case concerned whether privacy is protected as a fundamental right under the Indian Constitution.

The litigation arose in the context of challenges concerning the Aadhaar identification system, but the constitutional reference required the Court to determine the broader status of privacy within India's constitutional framework.

Legal issue

Whether privacy is a fundamental right and, if so, how State interference with privacy should be assessed.

Judgment

A unanimous nine-judge bench recognised privacy as a constitutionally protected fundamental right.

The judgment connected privacy with dignity, liberty, autonomy, and the protection of personal information.

It also established that restrictions on fundamental rights must satisfy appropriate constitutional standards.

For an invasion of privacy under Article 21, the judgment identified three essential requirements:

1. Legality: The interference must have a basis in law.
2. Legitimate State aim: The interference must pursue a legitimate objective.
3. Proportionality: The measure must bear a rational relationship to its objective and must not impose an unjustified restriction on the right.

The Court's judgment is available in the Supreme Court's official records and in the reported decision. Indian Kanoon

Application to biological sovereignty

The judgment is highly relevant when the State, a hospital, a biotechnology company, or a research institution collects or processes genetic information.

Suppose a public authority proposes to create a database containing individuals' genetic profiles for identification or predictive health analysis.

The legal analysis would need to consider:

• Whether the collection is authorised by law.
• Whether the purpose is legitimate.
• Whether collecting genetic information is necessary for that purpose.
• Whether less intrusive alternatives are available.
• Whether access and retention are appropriately limited.
• Whether adequate safeguards protect against misuse.

Genetic information may reveal more than identity. Depending on the data and analysis, it may also expose familial relationships, biological ancestry, or information about health-related characteristics.

Accordingly, the existence of a legitimate governmental objective does not automatically justify every form of biological-data collection.

Significance

Puttaswamy supplies a constitutional foundation for protecting individual biological autonomy against unjustified State interference.

It also demonstrates that State sovereignty is constrained by fundamental rights. The State may regulate biological resources and information, but its powers must be exercised consistently with the Constitution.

Case 3: Justice K.S. Puttaswamy (Retd.) v. Union of India — Aadhaar Judgment

Court: Supreme Court of India
Decision: 26 September 2018
Citation: (2019) 1 SCC 1

This judgment must be distinguished from the 2017 privacy decision.

Legal issue

Whether the Aadhaar framework and its collection and use of biometric and demographic information were constitutionally valid.

Judgment

The Court upheld important aspects of the Aadhaar framework while invalidating or restricting certain provisions and uses.

The judgment assessed biometric identification in the context of statutory authority, the purpose of delivering benefits and services, and the safeguards governing collection, retention, and use.

It did not establish that every collection of biometric information is constitutionally valid. Its reasoning depended on the statutory scheme and the particular uses and restrictions under examination. National Digital Library of India

Application to biological sovereignty

The decision illustrates the difference between biometric identification and unrestricted biological surveillance.

For example, a system that uses fingerprints or iris scans to authenticate an identity for a defined statutory purpose raises different questions from a system that combines biometric identifiers with genetic predictions, medical histories, or behavioural assessments.

The latter may involve substantially different privacy interests and legal justifications.

A biometric system's legality must therefore be assessed according to its actual design, purpose, data collected, recipients, retention rules, and available safeguards.

Significance

The Aadhaar judgment demonstrates that the State may lawfully require specified biometric information in certain circumstances, but such authority must be evaluated under the governing law and constitutional standards.

It does not confer an unrestricted power to collect DNA, conduct genetic profiling, or create biological rankings.

Case 4: Bhabani Prasad Jena v. Convenor Secretary, Orissa State Commission for Women

Court: Supreme Court of India
Decision: 2010
Citation: (2010) 8 SCC 633

Facts

The case concerned the circumstances in which a court may order DNA testing in a dispute involving paternity.

Legal issue

Whether a court should order a DNA test whenever scientific testing could help establish biological parentage.

Judgment

The Supreme Court emphasised that DNA testing is a sensitive matter involving privacy, family relationships, and the welfare and interests of the child.

It held that DNA testing should not be ordered routinely or merely to conduct a speculative inquiry.

The Court reconciled the principles in Goutam Kundu v. State of West Bengal and Sharda v. Dharmpal, emphasising the need for a strong prima facie case and careful judicial assessment before ordering a test. Sci API

Application to biological sovereignty

This decision is important because it demonstrates that scientific accuracy does not automatically override legal rights.

A DNA test may provide powerful evidence of biological relationships. Nevertheless, ordering the test can affect:

• Bodily privacy.
• Family relationships.
• The legal status and interests of a child.
• Confidentiality of genetic information.
• The dignity of the persons involved.

A court must therefore balance the evidentiary value of the test against the rights and interests affected by it.

Significance

The case supports a central principle of biological sovereignty governance:

The ability to obtain biological information does not, by itself, establish an unrestricted legal entitlement to obtain it.

Case 5: Sharda v. Dharmpal

Court: Supreme Court of India
Decision: 2003
Citation: (2003) 4 SCC 493

Facts

The dispute concerned medical examination in matrimonial proceedings and the circumstances in which a court may direct a party to undergo such an examination.

Legal issue

Whether a matrimonial court possesses the authority to order a medical examination and whether such an order necessarily violates personal liberty or privacy.

Judgment

The Supreme Court recognised that a court may, in appropriate circumstances, order a party to undergo a medical examination.

However, the power is not to be exercised arbitrarily. There must be sufficient grounds, and the court must carefully assess the circumstances of the case.

The decision was subsequently considered alongside Goutam Kundu and Bhabani Prasad Jena in determining when DNA or related medical testing may be justified. Sci API

Application to biological sovereignty

The decision illustrates that bodily autonomy is important but not absolute in every legal proceeding.

A judicially authorised examination may be permissible where the legal requirements are satisfied and the examination is relevant to the dispute.

Nevertheless, the power to order a medical examination does not establish an unlimited authority to collect, retain, or repurpose biological samples for unrelated purposes.

Significance

Sharda demonstrates the need to reconcile individual autonomy with legitimate judicial functions.

It is especially relevant when courts must determine whether biological evidence is necessary to resolve a dispute.

Case 6: Goutam Kundu v. State of West Bengal

Court: Supreme Court of India
Decision: 1993
Citation: (1993) 3 SCC 418

Legal issue

Whether a court may routinely order blood testing to determine paternity in proceedings involving the legal presumption of legitimacy.

Judgment

The Supreme Court held that blood tests should not be ordered as a matter of course. It emphasised the need for a strong prima facie case and consideration of the potential consequences for the parties and the child.

The decision established important safeguards against using scientific testing as a means of conducting speculative inquiries into family relationships.

Its principles were subsequently considered in Sharda and Bhabani Prasad Jena. Sci API

Significance for biological sovereignty

The case illustrates that biological evidence must be evaluated within a legal framework that protects privacy, family interests, and procedural fairness.

A person's biological characteristics cannot automatically be treated as information that anyone may compel them to disclose.

Case 7: Anvar P.V. v. P.K. Basheer

Court: Supreme Court of India
Decision: 2014
Citation: (2014) 10 SCC 473

This case is not a biological-sovereignty decision directly, but it is relevant to the broader governance of scientific and digital evidence.

Legal issue

The Court considered the admissibility requirements for electronic records under the Indian Evidence Act, 1872, particularly the certificate requirements under Section 65B.

Judgment

The Court established that the statutory requirements for admitting electronic records must be followed, subject to the applicable law and later developments in the evidentiary framework.

Application to biological sovereignty

Genomic databases, digital laboratory records, electronic consent forms, sequencing outputs, and computer-generated forensic reports may raise questions about authenticity, integrity, and admissibility.

However, Anvar P.V. does not establish a universal rule governing all biological evidence. Its principles must be applied in the context of the relevant evidence law.

For proceedings governed by the Bharatiya Sakshya Adhiniyam, 2023, the applicable provisions and commencement dates must be considered rather than automatically relying on the repealed Evidence Act.

Significance

The case illustrates that biological information used in legal proceedings must be handled within an appropriate evidentiary framework. Scientific reliability, lawful collection, authenticity, and admissibility are distinct questions.

5. Important International Case Laws

International decisions help explain the relationship between national sovereignty, Indigenous rights, personal autonomy, and commercial exploitation of biological materials.

Case 8: Saramaka People v. Suriname

Court: Inter-American Court of Human Rights
Decision: 2007

Facts and issue

The case concerned the rights of the Saramaka people, a tribal community in Suriname, in relation to natural resources and activities affecting their traditional territories.

The dispute raised questions about property rights, participation in decisions, and the conditions under which the State may authorise resource exploitation affecting Indigenous or tribal communities.

Judgment

The Court recognised protections relating to the community's property rights and held that major development or investment projects affecting traditional territory must comply with safeguards designed to protect the community's rights.

These safeguards include effective participation, appropriate benefit-sharing, and, in certain circumstances involving major projects with significant impacts, free, prior, and informed consent.

The judgment concerned Indigenous and tribal territorial rights and natural resources generally; it was not exclusively a case about genetic resources. ICLRC Biodiversity Legal Database

Relevance to biological sovereignty

The decision is important when biological resources are connected to traditional territories, cultural practices, or community livelihoods.

For example, a commercial enterprise seeking access to medicinal plants from a community's traditional territory may need to consider more than the government's regulatory permission.

Depending on the applicable legal framework, it may also need to respect community property rights, participation requirements, traditional knowledge protections, and benefit-sharing obligations.

Legal principle

National authority over natural resources does not automatically extinguish the rights of Indigenous or tribal communities.

Case 9: Kaliña and Lokono Peoples v. Suriname

Court: Inter-American Court of Human Rights
Decision: 2015

Facts and issue

The case concerned the rights of Indigenous peoples in Suriname in relation to traditional lands, natural resources, and protected areas.

Legal significance

The decision addressed Indigenous property rights and the need to recognise and protect the communities' relationship with their traditional territories.

It is relevant to biological sovereignty because biodiversity conservation, protected-area governance, and commercial exploitation of natural resources can affect Indigenous communities' rights.

The case illustrates the importance of ensuring that environmental governance does not simply exclude Indigenous communities from lands and resources with which they have longstanding relationships. ICLRC Biodiversity Legal Database

Application

When a State establishes a biodiversity reserve or regulates access to biological resources, it must consider any applicable legal obligations toward affected communities.

Conservation and community rights are not necessarily competing objectives. A properly designed framework can protect biodiversity while recognising legitimate community interests.

Case 10: Association for Molecular Pathology v. Myriad Genetics, Inc.

Court: Supreme Court of the United States
Decision: 2013
Citation: 569 U.S. 576

Facts

Myriad Genetics held patents relating to isolated DNA sequences associated with the BRCA1 and BRCA2 genes, which are relevant to hereditary breast and ovarian cancer risk.

The litigation challenged the patentability of naturally occurring human DNA sequences.

Legal issue

Whether naturally occurring DNA becomes patent-eligible merely because it has been isolated from the human body.

Judgment

The Supreme Court held that naturally occurring DNA segments are not patent-eligible under the relevant United States patent law merely because they have been isolated.

The Court distinguished naturally occurring DNA from complementary DNA, or cDNA, which may be patent-eligible depending on its characteristics and the applicable law.

Relevance to biological sovereignty

The judgment distinguishes the discovery of biological material from the creation of a patentable invention.

It demonstrates that discovering or isolating a biological feature does not necessarily confer an exclusive patent right over that naturally occurring feature.

However, the case did not establish that individuals own all their genetic information or that the State owns every naturally occurring gene.

Its central question concerned patent eligibility under United States law.

Significance

Biological sovereignty governance must distinguish among:

• Ownership or control of physical biological samples.
• Privacy rights in genetic information.
• Patent eligibility of inventions.
• Access to biological resources.
• Rights to commercialise resulting technologies.

These are separate legal questions.

Case 11: Moore v. Regents of the University of California

Court: Supreme Court of California
Decision: 1990
Citation: 51 Cal. 3d 120

Facts

John Moore received medical treatment for hairy-cell leukaemia. Biological materials obtained during his treatment were subsequently used in research and the development of a commercially valuable cell line.

Moore alleged that his physician had failed to disclose relevant financial and research interests and asserted claims concerning the use of his cells.

Legal issue

Whether a patient retained a property interest in excised cells sufficient to support a conversion claim under California law, and whether the physician's failure to disclose research and financial interests breached duties owed to the patient.

Judgment

The California Supreme Court rejected Moore's conversion claim concerning the excised cells under the circumstances presented.

However, it recognised the importance of informed consent and held that a physician's undisclosed research or financial interests could support a claim based on breach of fiduciary duty or lack of informed consent.

Relevance to biological sovereignty

The decision demonstrates that legal control over biological material is complex.

A person may have important rights concerning consent, medical disclosure, and the circumstances in which biological materials are obtained, even where the law does not recognise the particular property claim asserted.

The decision should not be interpreted as establishing a universal rule that individuals never have property rights in biological materials. Its holding arose under California law and the specific facts before the court.

Significance

Moore is a foundational comparative decision for understanding the tension between:

• Patient autonomy.
• Commercial biomedical research.
• Informed consent.
• Ownership claims concerning biological materials.
• Scientific innovation and financial incentives.

6. The Relationship Between Biological Sovereignty and Genetic Privacy

Biological sovereignty governance must address the fact that genetic information can reveal highly personal characteristics.

A DNA sample may potentially reveal information about an individual's biological relationships, ancestry, and certain health-related characteristics. It can also contain information relevant to biological relatives who have never provided samples themselves.

Consequently, the legal consequences of collecting a DNA sample may extend beyond the person who physically supplied it.

Key legal questions

1. Can the government collect DNA without consent?

There is no universal answer. The result depends on the applicable law, the purpose of collection, the circumstances, and constitutional safeguards.

Forensic collection, medical testing, research, and population-wide genetic screening raise different issues.

2. Can a company sell genetic data?

The answer depends on the applicable data-protection rules, consent arrangements, contractual obligations, and any special restrictions on the information concerned.

A person's agreement to one use of genetic information should not automatically be assumed to authorise every unrelated secondary use.

3. Can genetic data be used to make employment or insurance decisions?

Such use may raise privacy, discrimination, consumer-protection, and other legal issues. The precise prohibition or remedy depends on the jurisdiction and applicable legislation.

4. Can a court compel DNA testing?

Indian decisions such as Goutam Kundu, Sharda, and Bhabani Prasad Jena show that the judicial power to order testing must be exercised carefully and according to the circumstances of the case.

Constitutional test

Where State action interferes with genetic privacy protected by Article 21, the Puttaswamy framework provides an important starting point.

The authority must identify a legal basis, establish a legitimate aim, and justify the interference under the applicable proportionality standard.

A system that stores genetic information indefinitely for unspecified future purposes may therefore raise different constitutional concerns from a narrowly defined and lawfully authorised forensic test.

7. Biological Sovereignty and Indigenous Communities

One of the most important dimensions of biological sovereignty is the relationship between biodiversity, traditional knowledge, and the rights of Indigenous peoples and local communities.

Traditional knowledge may concern medicinal plants, seed preservation, agricultural techniques, microorganisms, and other biological resources. Commercial exploitation of that knowledge can create disputes about consent, compensation, attribution, and control.

A. Prior informed consent

Prior informed consent is a mechanism through which authorised persons or institutions give permission for access to biological resources or associated knowledge before the relevant activity occurs, where the applicable legal framework requires it.

Under Article 6 of the Nagoya Protocol, access to genetic resources is subject to prior informed consent where required by the providing country's access-and-benefit-sharing framework. Article 7 addresses traditional knowledge associated with genetic resources. Convention on Biological Diversity

In practice, consent arrangements should identify:

• The biological resources or knowledge concerned.
• The intended research or commercial purpose.
• The parties authorised to provide consent.
• Permitted transfers to third parties.
• The applicable benefit-sharing arrangements.
• Conditions governing subsequent use.
• Procedures for resolving disputes.

The precise legal requirements depend on the relevant domestic law and the rights of the parties concerned.

B. Fair and equitable benefit-sharing

Benefit-sharing aims to ensure that the benefits arising from the utilisation of genetic resources and associated traditional knowledge are distributed fairly under the applicable framework.

Benefits may include:

1. Monetary payments.
2. Royalties or agreed commercial returns.
3. Research collaboration.
4. Training and scientific capacity-building.
5. Technology transfer.
6. Participation in research and development.
7. Contributions to conservation.
8. Other agreed monetary or non-monetary benefits.

Article 5 of the Nagoya Protocol addresses benefit-sharing with providing countries and, subject to the applicable legal framework, Indigenous and local communities holding relevant resources or traditional knowledge. Convention on Biological Diversity

C. Example

Suppose a pharmaceutical company uses traditional knowledge about an Indian medicinal plant to develop a commercially successful product.

The legal analysis should consider:

• Whether access to the biological resource was lawful.
• Whether the knowledge was accessed in accordance with applicable requirements.
• Whether the company obtained the necessary approvals.
• Whether benefit-sharing obligations apply.
• Whether any intellectual-property rights are available.
• Whether the community possesses relevant rights under domestic law.
• Whether the company's contractual commitments have been fulfilled.

The company's ability to obtain a patent or commercialise a product does not automatically eliminate independent obligations concerning access, consent, or benefit-sharing.

Equally, the existence of traditional knowledge does not automatically confer ownership of every later invention on the community. Each issue requires a separate legal analysis.

8. Biological Sovereignty and Intellectual Property Rights

Biological sovereignty governance frequently creates questions about the relationship between biological resources and intellectual-property protection.

A company may obtain biological material lawfully, conduct research, and develop a new product. Whether the company can obtain a patent depends on the applicable patent law and the characteristics of the claimed invention.

A. Biological resources are not automatically patentable

In India, the Patents Act, 1970 contains exclusions relevant to biological material, plants, animals, traditional knowledge, and certain discoveries.

For example:

• Section 3(c) excludes the mere discovery of a scientific principle or the formulation of an abstract theory, as well as the discovery of something occurring in nature, within the statutory language.
• Section 3(j) addresses plants and animals, in whole or in part, other than microorganisms, and excludes seeds, varieties, and species and essentially biological processes for the production or propagation of plants and animals.
• Section 3(p) addresses inventions that are, in effect, traditional knowledge or an aggregation or duplication of known properties of traditionally known components.

Other provisions may also apply, depending on the invention.

Official statutory materials are available through India Code.

B. Relationship between patents and biodiversity regulation

Patent eligibility and lawful access are different questions.

For example, a researcher may develop a technically novel process using a biological resource. Even if the process satisfies the relevant patentability requirements, separate questions may arise concerning whether the resource was obtained lawfully and whether applicable access-and-benefit-sharing obligations were met.

Conversely, obtaining all necessary biodiversity approvals does not guarantee that the resulting invention is patentable.

C. Relevant case law

The United States Supreme Court's decision in Association for Molecular Pathology v. Myriad Genetics, Inc. (2013) illustrates the distinction between discovering naturally occurring genetic material and creating an invention that qualifies for patent protection.

The decision is persuasive for comparative analysis, but its interpretation of United States patent law does not determine the meaning of India's Patents Act.

The governing principle is that regulatory permission, ownership, informed consent, benefit-sharing, and patentability must be assessed independently.

9. Biological Sovereignty and Public Health Emergencies

Public-health emergencies create a difficult tension between national authority, individual rights, scientific cooperation, and the need to share biological information quickly.

Examples include:

• Outbreaks of infectious diseases.
• Collection of pathogen samples.
• Genome sequencing of emerging viruses.
• Cross-border exchange of biological materials.
• Emergency vaccine development.
• Surveillance of antimicrobial resistance.
• Access to essential medicines and vaccines.

A. State powers and limitations

A State may possess statutory authority to implement public-health measures, collect specified information, or regulate the movement of biological materials.

However, such powers must be exercised within the relevant legal framework. Constitutional rights, statutory safeguards, international obligations, and the rights of affected persons may remain applicable.

B. International cooperation

Biological sovereignty should not be confused with an unrestricted right to withhold all biological information from other countries.

International public-health systems depend on scientific collaboration, timely information exchange, and access to relevant samples and research findings.

The Nagoya Protocol itself recognises the importance of access to human pathogens for public-health preparedness and response, while acknowledging the need for consistency among relevant international frameworks. Convention on Biological Diversity

The legal treatment of human pathogens may differ from the treatment of other genetic resources, depending on the applicable instrument and domestic legislation.

C. Example

Suppose a laboratory identifies a previously unknown pathogen and sequences its genome.

The laboratory and relevant authorities may need to consider:

1. The lawful collection and possession of the sample.
2. Applicable biosafety and biosecurity requirements.
3. Obligations to notify public-health authorities.
4. Rules governing cross-border transfers.
5. Confidentiality and data-protection obligations.
6. Research agreements and applicable benefit-sharing rules.
7. Restrictions on dangerous or unauthorised uses.

A State's interest in protecting its population must be balanced with applicable international obligations and the need for effective scientific cooperation.

10. Biological Sovereignty and Artificial Intelligence

Advances in artificial intelligence create new questions for biological sovereignty governance.

AI systems can analyse genomic data, predict disease risks, identify biological patterns, assist in drug discovery, and support decisions involving healthcare and biotechnology.

These capabilities can improve research, but they can also create risks involving discrimination, privacy, accountability, and unequal access to scientific benefits.

A. Algorithmic use of biological information

Suppose a government develops an AI system that predicts disease susceptibility using genetic information.

The system could potentially support public-health planning. However, it might also create risks if predictions are used to exclude individuals from employment, insurance, education, or public services without a lawful basis.

Relevant legal questions include:

• Was the genetic information collected lawfully?
• Was the intended use disclosed?
• Is the system sufficiently reliable for the decision being made?
• Does the system discriminate unlawfully?
• Can an affected person challenge the decision?
• Is sensitive information being retained longer than necessary?
• Who is responsible when the system produces an erroneous result?

B. Automated biological classification

A more controversial example would be a government system that assigns people a biological score based on genetic characteristics, predicted health risks, or physiological measurements.

If such a score determines access to public benefits, employment opportunities, or other essential services, it could raise serious constitutional concerns.

Under Indian law, the relevant analysis may involve Articles 14 and 21, together with applicable data-protection and sector-specific legislation.

A system that uses biological information to make consequential decisions should not be assumed lawful merely because it is technically sophisticated.

C. Biological social-credit systems

Biological sovereignty governance is particularly relevant to systems that rank individuals according to biological or genetic characteristics.

A system that assigns people a score based on genetic predispositions, biological productivity, predicted longevity, or health characteristics raises questions concerning:

1. Constitutional equality.
2. Privacy and bodily autonomy.
3. Discrimination and human dignity.
4. The reliability of scientific predictions.
5. Transparency of decision-making.
6. The availability of meaningful review and remedies.

There is no single Indian Supreme Court judgment establishing a complete legal doctrine for all such hypothetical systems.

Their legality would depend on the particular design, purpose, decision-making consequences, statutory authority, and rights affected.

The principles established in Puttaswamy, together with applicable equality and data-protection law, provide a foundation for evaluating these systems.

11. Institutional Accountability in Biological Sovereignty Governance

Effective biological sovereignty governance requires more than substantive rules. It also requires accountable institutions.

A. Clear statutory authority

Regulators should exercise only those powers conferred by the applicable legislation.

A government department cannot automatically claim authority over every genetic database, biological sample, or biotechnology invention merely because the subject matter involves biology.

B. Transparency

Where legally appropriate, regulatory decisions should explain:

• The legal basis for the decision.
• The evidence relied upon.
• The conditions imposed.
• The reasons for refusing access or approval.
• The applicable review and appeal procedures.

Commercial confidentiality, personal privacy, and national-security restrictions may justify limiting particular disclosures, but such restrictions must themselves have an appropriate legal basis.

C. Scientific reliability

Regulatory decisions based on genetic predictions or biological evidence should take account of scientific validity.

A genetic association does not necessarily establish that an individual will develop a particular disease. Similarly, a statistical prediction should not automatically be treated as proof of an individual's future conduct or capabilities.

D. Independent review

Depending on the governing law, affected individuals and organisations may be able to challenge decisions through administrative review, statutory appeals, judicial review, or other legal remedies.

E. Accountability for misuse

Misuse of biological information may engage multiple legal regimes, including data protection, confidentiality, employment law, consumer protection, criminal law, professional regulation, and constitutional remedies.

The appropriate remedy depends on the conduct and the law applicable to it.

12. Major Legal Challenges

Biological sovereignty governance faces several unresolved or evolving challenges.

The table is a framework for identifying issues, not a substitute for examining the legislation applicable to a particular transaction.

13. Practical Legal Test for Biological Sovereignty Governance

When analysing a dispute concerning biological sovereignty, the following eight-step framework can be useful.

Step 1: Identify the biological subject matter.

Determine whether the dispute concerns human biological material, genetic information, a plant, an animal, a microorganism, a pathogen, traditional knowledge, or a biotechnology invention.

Step 2: Identify the relevant rights-holder.

Determine whether the relevant interests belong to an individual, a community, a research institution, a private company, a landholder, or the State.

Several parties may hold different rights in the same biological resource or resulting information.

Step 3: Identify the applicable law.

Determine which constitutional provisions, statutes, regulations, contracts, and international obligations apply.

Step 4: Establish lawful access.

Examine whether collection, possession, sequencing, testing, transfer, or commercial utilisation required permission or consent.

Step 5: Examine the purpose of use.

Distinguish medical treatment, forensic testing, scientific research, conservation, commercial development, and public-health surveillance.

Permission for one purpose should not automatically be assumed to authorise every other purpose.

Step 6: Assess rights and safeguards.

Consider privacy, bodily autonomy, equality, confidentiality, Indigenous and community rights, scientific validity, and procedural fairness.

Step 7: Examine benefits and intellectual property.

Determine whether benefit-sharing obligations apply and whether the resulting invention satisfies the relevant intellectual-property requirements.

Step 8: Identify remedies and accountability.

Consider whether a decision can be challenged through judicial review, statutory appeal, a data-protection remedy, contractual proceedings, or another applicable legal mechanism.

This framework helps distinguish State authority from ownership, scientific capability from legal permission, and commercial opportunity from lawful entitlement.

14. Conclusion

Biological Sovereignty Governance is an important legal framework for understanding the relationship between States, individuals, communities, scientific institutions, and private enterprises in the management of biological resources and information.

Its central concern is not simply who owns biological material. It is how authority, access, consent, privacy, benefits, and accountability should be distributed and regulated.

The principal legal conclusions are:

State sovereignty is not unlimited ownership. A State may regulate access to biological resources without automatically owning every biological sample or resulting invention.

Individual biological autonomy deserves legal protection. Genetic information, bodily integrity, and medical consent may engage fundamental rights, particularly under Article 21 of the Indian Constitution.

Community rights must be considered. Commercial use of biological resources and traditional knowledge may trigger consultation, consent, or benefit-sharing requirements under the applicable framework.

Scientific capability does not create automatic legal authority. The ability to collect DNA, predict disease, or classify biological characteristics does not establish an unrestricted right to do so.

Commercialisation and patentability are separate questions. A company must satisfy the relevant requirements for both lawful access and any intellectual-property protection it seeks.

Regulatory decisions must remain accountable. Statutory authority, constitutional safeguards, scientific reliability, and appropriate review mechanisms are essential components of legitimate biological governance.

Most important cases to remember

Final principle: Biological sovereignty governance seeks to ensure that control over biological resources and information is exercised lawfully, individual dignity is protected, community interests are respected, scientific research remains possible, and the benefits of biotechnology are distributed in accordance with applicable legal obligations.